Related by context. Frequent words. (Click for all words.) 72 MKC# MT 72 Completes Patient Enrollment 72 VEGFR2 inhibitor 72 Initiates Phase II 71 XL# XL# XL# XL# 71 oncolytic virus therapies 71 PNP inhibitor 70 Panzem R 69 2 methoxyestradiol 69 Receives Orphan Drug Designation 69 phenylalanine ammonia lyase 69 Meets Primary Endpoint 68 Drug Candidate 68 refractory chronic lymphocytic 68 PEG PAL PEGylated recombinant 67 Completes Enrollment 67 Panzem R NCD 67 Presents Positive 67 Anti Tumor 67 MKC# 67 inflammatory autoimmune diseases 67 Preclinical Data 67 BiovaxID TM 66 Idera Pharmaceuticals develops 66 CORT # 66 ALN TTR 66 Commences Phase 66 Initiate Phase 66 TELINTRA 66 signal detection CTSD 66 Empatic TM 66 Clinical Trial Results 66 multicenter Phase III 66 Kinase Inhibitor 66 ALN PCS 66 Initiates Phase 66 based pretargeting methods 66 CD#.# DOES NOT ENDORSE 65 XOMA 3AB 65 TRAIL receptor antibodies 65 regarding Aethlon Medical 65 R sorafenib tablets 65 peripherally acting 65 Romidepsin 65 Dyax logo 65 HOW LONG WAS 65 Cutaneous T 65 Marcus Gronholm BP 64 neuro inflammatory 64 non personalized allogeneic 64 PEGylated anti 64 Sapacitabine 64 Recombinant Human 64 Inovio clinical 64 generation proteasome inhibitor 64 Entereg R 64 Study Evaluating 64 Regulatory Disclosure 64 YOUR LOCAL ANIMAL SHELTER 64 Enrolls First 64 MGCD# MGCD# [001] 64 SAR# [002] 63 HGS ETR2 63 D aspartate NMDA receptor 63 PSN# [002] 63 Phase Ib clinical trials 63 JAK1 63 Previously Treated 63 CCX# 63 Pimavanserin 63 Thiarabine 63 forodesine 63 ® bortezomib 63 Pivotal Phase 63 Pivotal Phase III 63 development diagnostics combinatorial 63 PEG SN# 63 sorafenib tablets 63 Voreloxin 63 www.adeonapharma.com 63 catheter occlusion 63 BY MICHAEL PUFFER 63 BY JIM HAND 63 NEBIDO R 63 PINNACLEDIGEST.COM S PAST PERFORMANCE 63 Takeda Kyowa Hakko Kirin 63 www.syntapharma.com 63 By Thomas Gryta 63 histone deacetylase HDAC inhibitor 63 http:/www.idenix.com 63 Epratuzumab 63 proteasome inhibitor 62 novel orally administered 62 BY JONATHAN SHUGARTS 62 Palifosfamide Zymafos TM 62 BY MARK FARINELLA 62 overactive bladder AA# 62 Patient Enrollment 62 Metastatic Melanoma 62 LungAlert TM 62 www.vivus.com